Showing 2891-2900 of 6036 results for "".
- Jazz to Buy Cannabinoid Drugmaker GW Pharma in $7.2-Billion Dealhttps://modernod.com/news/jazz-to-buy-cannabinoid-drugmaker-gw-pharma-vva-7-2-billion-deal/2478832/Jazz Pharmaceuticals entered into a definitive agreement to acquire GW Pharmaceuticals for $220 per share, or a total consideration of $7.2 billion, adding the latter’s cannabinoid product platform, including Epidiolex (cannabidiol), to its neuroscience pipeline, the companies announced Wed
- NeuroVision Imaging Receives Funding From the ADDF to Develop Biomarkers to Diagnose Alzheimer’s and Related Dementiashttps://modernod.com/news/neurovision-imaging-receives-funding-from-the-addf-to-develop-biomarkers-to-diagnose-alzheimers-and-related-dementias/2478823/NeuroVision Imaging announced it has received an investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to support developing reliable, affordable biomarker tests for Alzheimer’s disease and other forms of dementia and neurodegenerative disorders. “Many of the existing diagnostic
- Lensar Expands Board of Directors with the Appointments of Aimee S. Weisner and Elizabeth G. O’Farrellhttps://modernod.com/news/lensar-expands-board-of-directors-with-the-appointments-of-aimee-s-weisner-and-elizabeth-g-ofarrell/2478817/Lensar announced the expansion of its board of directors to seven members with the appointments of Aimee S. Weisner and Elizabeth G. O’Farrell, effective February 1, 2021. In addition to serving on the company’s Board of Directors, Ms. Weisner will
- Leo Lens Pharma Announces Corporate Name Change to MediPrint Ophthalmicshttps://modernod.com/news/leo-lens-pharma-announces-corporate-name-change-to-mediprint-ophthalmics/2478794/Leo Lens Pharma has announced a corporate name change to MediPrint Ophthalmics, effective immediately. The company also announced it has successfully closed an over-subscribed Seed round fundraising. The company’s rebranding to MediPrint Ophthalmics is based on input from stakeholders and
- MeiraGTx Announces AAV-CNGA3 Granted Fast Track Designation by FDA for Treatment of Achromatopsiahttps://modernod.com/news/meiragtx-announces-aav-cnga3-granted-fast-track-designation-by-fda-for-treatment-of-achromatopsia/2478795/MeiraGTx Holdings announced that the FDA has granted Fast Track designation to its AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM) caused by mutations in the CNGA3 gene. ACHM is an inherited retinal disease that severely limits a per
- Keeler Partners With Merakris Therapeutics, Developer of Biological Barrier Grafthttps://modernod.com/news/keeler-patners-with-merakris-therapeutics-developer-of-biological-barrier-graft/2478785/Keeler has announced its partnership with Merakris Therapeutics, which is developing commercially scalable biotherapeutic technologies derived from stem cells that promote homeostasis in damaged tissue. Terms of the deal were not disclosed. “We are excited. This partnership accelera
- Market Scope: Refractive Surgery to Grow 9.6% a Year Through 2025, Despite COVID-19https://modernod.com/news/market-scope-refractive-surgery-to-grow-9-6-a-year-through-2025-despite-covid-19/2478774/Expanding use of products to treat refractive error will increase the role of devices and surgical procedures in the refractive landscape, according to a new Market Scope report. Globally, over 2.3 billion people require vision correction and have access to ophthalmic care. Global demand f
- CooperVision Announces 5 mm BOZD Customization for Paragon CRT and CRT Dual Axis Lenseshttps://modernod.com/news/coopervision-announces-5-mm-bozd-customization-for-paragon-crt-and-crt-dual-axis-lenses/2478769/CooperVision Specialty EyeCare announced that it has begun offering 5 mm back optic zone diameter (BOZD) customization for Paragon CRT and Paragon CRT Dual Axis contact lenses. The new option joins several existing customization choices, further expanding myopia management possibilities for eye c
- Gemini Therapeutics Announces FDA Fast Track Designation Granted for GEM103 for Investigational Dry AMD Treatmenthttps://modernod.com/news/gemini-therapeutics-announces-fda-fast-track-designation-granted-for-gem103-for-investigational-dry-amd-treatment/2478737/Gemini Therapeutics announced that GEM103, the company’s investigational treatment for dry AMD, has been granted Fast Track designation by the FDA. Gemini is evaluating GEM103, a recombinant, human complement factor H (CFH), for its ability to address the multiple AMD pathobiologies in gene
- Haag-Streit Introduces Lenstar Myopia for Myopia Managementhttps://modernod.com/news/haag-streit-introduces-lenstar-myopia-for-myopia-management/2478732/Haag-Streit has announced the launch of Lenstar Myopia, a solution for myopia management and patient education. Lenstar Myopia consists of the Lenstar 900 optical biometer and the corresponding EyeSuite software, EyeSuite Myopia. EyeSuite Myopia uses the latest axial length growth curves f